Eli Lilly Shareholders Re-elect Directors; Governance Proposals Fail Amid Revenue Growth
At Eli Lilly's 2026 annual meeting, all four incumbent directors were re-elected and Ernst & Young was ratified as auditor. However, management proposals to end the classified board structure and remove a supermajority voting requirement failed. CEO Dave Ricks highlighted a 45% revenue increase in 2025 driven by products like Mounjaro and Zepbound.
Tickers: $LLY
Topics: directors re-elected Eli Lilly governance proposals failed revenue growth shareholder meeting